On April 20, 2024, the "2024 11th 301 Health Theory, National Health Action (Xiong'an) Forum and the 13th Academic Forum of the Director of the Physical Examination Center" hosted by the China Health Management Association and the Public Service Bureau of Xiong'an New Area, and organized by the Second Medical Center of the PLA General Hospital, the Health Examination Branch of the China Health Management Association, the Physical Examination and Evaluation Group of the Health Management Branch of the Chinese Medical Association, and the National Clinical Research Center for Geriatric Diseases (PLA General Hospital) was held in Xiong'an New Area. With the theme of "Focusing on the International Frontier and Leading the Development of Disciplines", the "301 Discussion on Health" as an academic brand forum and industry event of international standards for health management, supported by the National Biochip Standardization Technical Committee and Beijing Boao Yihe Zekang Technology Co., Ltd., was successfully held.
In April 2014, the first national standard in the field of disease susceptibility gene detection jointly drafted by Boao Biotechnology Co., Ltd., Shanxi Provincial Cancer Hospital and the Affiliated Hospital of Ningxia Medical University - "Human Disease Susceptibility DNA Polymorphism Detection Gene Chip" (hereinafter referred to as the national standard) was promulgated and implemented by the National Biochip Standardization Technical Committee. April 2024 coincides with the 10th anniversary of the promulgation of national standards. "Ten years of foundation, starting from the core", this "Disease Susceptibility Gene Chip National Standard Symposium" aims to summarize and review the application and social contributions made in the past ten years since the promulgation of the national standard, with susceptibility gene testing as the core foundation, promote the development of new quality productivity in the health management industry, and promote the "precision health management model adjusted according to the test", so as to achieve the goal of active health and healthy China.
The conference was presided over by Wang Peng, vice chairman of the National Health Examination and Management Professional Quality Control Center, President of the Airport Campus of Peking University Third Hospital, and Mei Ying, member of the Physical Examination and Evaluation Group of the Health Management Branch of the Chinese Medical Association, and director of the Health Medicine Center of the Second Affiliated Hospital of Chongqing Medical University. Zeng Qiang, director of the Health Management Research Institute of the Second Medical Center of the PLA General Hospital, executive director of the Functional Medicine Branch of the China Health Management Association, Wang Guoqing, chairman of Beijing Boao Yihe Zekang Technology Co., Ltd., and many other senior experts in the field of domestic health made special reports, and the experts shared the latest research results in the field of susceptibility genes and chronic disease health management, from the research on susceptibility genes in the prevention and control of chronic obstructive pulmonary disease, the prevention and control of susceptible genes in adolescents with high myopia, and the release of "key technology research on precision nutrition intervention for obesity" The project reviewed the fruitful achievements and contributions of the national standard for disease susceptibility gene chips in the past ten years.
The scene of the symposium on the national standard of disease susceptibility gene chips
Ten years of building the foundation of the national standard, health starts from the core
The seminar kicked off with the speech of Secretary General Xing Wanli of the National Biochip Standardization Technical Committee. Secretary-General Xing Wanli said that the promulgation of the national standard "Human Disease Susceptibility DNA Polymorphism Detection Gene Chip" in 2014 provides guidance for human disease susceptibility gene testing, which is an important symbol in the field of disease prediction and prevention of Chinese, and a powerful witness to China's biochip scientific and technological innovation, which makes Chinese human disease susceptibility gene detection gradually become an important force in China's health industry, and is the national health field "from prevention-centered to people's health-centered" Effective means and methods of strategic adjustment, the national standard ten years is not only a witness to the past history, but also marks a new journey, the beginning of the "core" mission. It is hoped that the susceptibility gene chip technology based on national standards can expand the application field, better serve healthy China, serve health management, and do a good job in the prevention and control of chronic diseases in China.
Xing Wanli, Secretary-General of the National Biochip Standardization Technical Committee, delivered a speech
Based on the national standard, build a precise health management model that adjusts according to the test
The Chinese Guidelines for Lung Cancer Screening, Early Diagnosis and Early Treatment clearly point out six major risk factors for lung cancer, two of which are chronic obstructive pulmonary disease history and genetic predisposition. At the seminar, Gao Zhancheng, director of the Department of Respiratory and Critical Care Medicine of Peking University People's Hospital, made a report on "Research on the Application of Susceptibility Genes to the Prevention and Control of COPD", which pointed out the important role of Chinese reference genomes in the process of disease risk assessment.
The prevention and control of adolescent myopia has risen to the national strategic level, and Li Jinghan, director of Shenyang He's Eye Hospital, brought the "Research Results of Susceptibility Genes Applied to High Myopia in Adolescents in Liaoning Province" to share, telling that Liaoning He's Ophthalmology lasted four years and investigated more than 950,000 people in total. The myopia degree of children and adolescents was stable, which was much higher than that of the non-strict enforcement group (38.05%).
The incidence of chronic metabolic diseases is increasing rapidly. Individualized precision nutrition based on nutrigenomic technology can effectively prevent and improve chronic metabolic diseases. The PLA General Hospital and Boao Biotech have had a solid foundation of scientific research cooperation in the field of metabolic disease intervention for many years, and the weight-loss products jointly developed by the two parties won the first prize of China's industry-university-research cooperation innovation achievement in 2018, the first prize of invention and entrepreneurship achievement of China Association of Inventions and obtained an invention patent. The two sides will continue to work together to further deepen the research on the prevention and treatment of metabolic diseases, and jointly applied for the project of "Key Technology Research on Precision Nutrition Intervention for Obesity" with the China Health Promotion Foundation. At this seminar, Zeng Qiang, director of the Institute of Health Management of the PLA General Hospital, released the topic, encouraging and calling on experts and colleagues in the field of medical and health management to actively participate in exploring innovative solutions for precision health.
As one of the formulators, promoters and practitioners of the national standard for disease susceptibility gene chips, Wang Guoqing, chairman of Beijing Boao Yihe Zekang Technology Co., Ltd., summarized and reviewed the role and contribution of the "Ten Years of Achievements in the Promulgation of the National Standard for Disease Susceptibility Gene Chips" at the seminar, and the detection products and services of susceptibility gene chips have been applied in the market for more than ten years, serving more than 300 tertiary hospitals and providing genetic testing services for 500,000 subjects.
Gao Zhancheng, director of the Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, reported on "Research on the Application of Susceptibility Genes to the Prevention and Control of COPD".
Li Jinghan, director of Shenyang He Eye Hospital, reported on the research results of susceptibility genes applied to high myopia in adolescents in Liaoning Province
Wang Guoqing, chairman of Beijing Boao Yihe Zekang Technology Co., Ltd., reported on the "Review of the Ten Years of Achievements in the Promulgation of the National Standard for Disease Susceptibility Gene Chips".
Zeng Qiang, director of the Health Management Research Institute of the Second Medical Center of the PLA General Hospital, released the topic of "Research on Key Technologies of Precision Nutrition Intervention for Obesity".
In order to recognize the outstanding contributions made by various institutions to the cause of health management on the basis of the national standard for susceptibility gene chips, awards were presented at the seminar in a grand atmosphere. Based on the susceptibility gene detection products developed by the national standard, Shanghai Sixth People's Hospital has made outstanding contributions to the effective intervention of obese people in the community of Shanghai Sixth People's Hospital and the Second Medical Center of the General Hospital of the Chinese People's Liberation Army, both of which have won the achievement achievement award. The Social Contribution Award was won by Liaoning He's Eye Hospital Group Co., Ltd., which used susceptibility gene detection technology to provide scientific and personalized myopia prevention and control programs for children in Liaoning Province, successfully reduced the overall myopia rate of adolescents, and released the "White Paper on the Prevention and Control of High Myopia among Adolescents in Liaoning Province".
Disease Susceptibility Gene Testing Achievement Transformation Award
Social Contribution Award for Disease Susceptibility Genetic Testing
Develop new quality productivity and lead the health industry with scientific and technological innovation
In the ten years since the promulgation of the national standard, fruitful results have been achieved in the field of disease prediction and prevention, but it is also facing many challenges and opportunities. The growing social demand and scientific and technological progress have given birth to the driving force of continuous innovation in health management. As the main force of Beijing Boao Jingdian Biotechnology Co., Ltd.'s strategic layout in the field of health, Beijing Boao Yihe Zekang Technology Co., Ltd. undertakes the development and testing services of human disease susceptibility gene testing, the company focuses on building a sustainable development of the Chinese precision health management ecosystem, adhering to the concept of "adjusting according to testing", taking comprehensive testing and comprehensive evaluation as the core, building a precision health management model based on testing, and contributing innovative scientific and technological products and services to active health and healthy China.